" if any have yet been able to cross the brain blood barrier."
"Roche has claimed the latest phase 2 readout for its multiple sclerosis (MS) drug backs up the BTK inhibitor’s "best in disease" potential by achieving the "holy grail" in biopharma: crossing the blood-brain barrier."
Not relevant to what PAB are doing but looks like they are catching up. Link to article below -
Roche BTK inhibitor may show 'holy grail' of brain penetration (fiercebiotech.com)
Ann: Appendix 4E and 2023 Annual Report, page-22
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.001(14.3%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $2.916K | 398.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 3479285 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |